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Background: Access to medicines is a universal right. Low availability and low affordability of medicines are issues
that deny this right to a significant proportion of the world population. The objective of this study was to
determine the availability, price and affordability of essential medicines prescribed to treat non communicable
diseases in Sri Lanka.
Methods: Methodology was based on the 2nd edition of the World Health Organization Health Action
International Manual. A country survey was conducted and facilities representing both public and private
pharmacies were selected. A total of 109 facilities was surveyed. At each facility data on the availability and prices
of 50 essential medicines for non communicable diseases were collected. Percentage availability, median price of
originator brand and lowest priced generic, median price ratio to the International Reference Price were calculated
for surveyed medicines. Affordability was determined using the daily incomes of the lowest - paid unskilled
government worker.
Results: Semi government community pharmacies had the highest (>80%) availability while outdoor pharmacies
of public health care facilities, private pharmacies and outdoor pharmacies of private hospital showed a fairly high
availability (50 - 80%) of surveyed medicines.
Unit price of 76% of selected individual medicines was less than ten Sri Lankan rupees. Out of these 28% of
medicines cost less than one Sri Lanka rupee. For 21 of the surveyed medicines the median price ratio to the
international reference price was less than one. The prices of originator brands for 14 surveyed medicines were
more than five times that of the lowest price generics.
Less than a single day’s wages was adequate to purchase a month's supply of the lowest priced generic of more
than 67% of surveyed medicines.
Conclusions: The availability of selected essential medicines was fairly high in both public and private sectors in
Sri Lanka. Most medicines are affordable to the lowest income earners in the community. There were many generic
brands and generics available for most of the medicines in private and semi government community pharmacies
increasing both availability and affordability.
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Medicines that satisfy the healthcare needs of the major-
ity of the population are defined as Essential Medicines
(EM) [1]. They save lives, reduce suffering and improve
health only if they are of good quality, safe, available and
affordable. Selection of EM is based on the disease
prevalence, evidence on efficacy, safety and comparative
cost effectiveness in a particular country [2]. In addition
to these the Sri Lanka essential medicines list (SL-EML)
was compiled after considering the stability in various
conditions, the needs of special diagnostic or treatment
facilities and pharmacokinetic properties of drugs [3].
Availability and affordability are preconditions for uni-
versal access. Access is defined as having medicines
continuously available and affordable at public or private
health facilities or drug outlets that are within one hour’s
walk from homes of the population [1]. Affordability is
measured by the cost required to buy a medication
course for the indicated time for a particular disease in
terms of the daily wage of the lowest-paid unskilled gov-
ernment worker [1]. Access to health care is a funda-
mental right and is included in international agreements
and governmental policies. This fundamental right can
be fulfilled by access to EM for priority diseases and is
considered as one of the UN’s Millennium Development
Goals (MDGs) [4].
Many factors affect access to medicines. Unaffordable
medicine prices, poor availability, irrational use of medi-
cines, unfair health financing mechanisms, unreliable
medicines supply systems, the quality of medicines and
poor adherence of patients are among the factors that
affect access to medicines [2].
Each year, chronic diseases cause approximately 35
million deaths (60% of all deaths) globally with more
than 30 million deaths (52% of all deaths) due to cardio-
vascular diseases [5]. A significant proportion of morbidity
and mortality due to chronic diseases can be prevented if
medicines are made accessible and affordable. When
medicines are used appropriate to control cardiovascular
diseases, a cumulative relative risk reduction of about 75%
can be achieved [6].
Yet one third of the global population lacks reliable ac-
cess to needed medicines. It is worst in the poorest
countries in Africa and Asia, where 50% of population
lacks access to medicines [4]. In a study done in 36 low
and middle income countries in 2001–2006, the mean
availability of EMs for non communicable diseases
(NCD) was 36% in the public sector and 55% in the pri-
vate sector [7] and the median availability of EM for
chronic diseases in six low- and middle-income coun-
tries was less than 7.5% [8]. The probability of patients
receiving at least one medicine for secondary prevention
of cardiovascular disease depends on the country’s in-
come. It was 19 · 8% in low-income countries, 30 · 7% inlow-income and middle-income countries, and 54 · 9%
for upper-middle-income countries [9].
Availability of EM depends on the country budget for
health. Average per capita spending on pharmaceuticals in
high-income countries is 100 times higher than that of low-
income countries [4]. The World Health Organization
(WHO) estimates that 15% of the world’s population
consumes over 90% of the global production of pharma-
ceuticals [4]. Compared to less than 10% allocation for
medicines by most high income countries, the develo-
ping countries allocate 25-70% of overall health care ex-
penditure for medicines [4]. However more medicines
can be acquired within existing budgets with efficient se-
lection, procurement, and use of generic medicines [7].
The NCD burden is increasing in Sri Lanka [10-12].
Of the 11 South East Asian Region (SEAR) countries, Sri
Lanka ranks third with NCD accounting for 66% of total
deaths [12]. The proportion of deaths due to circulatory
diseases in Sri Lanka have increased from 3% to 24%
over the last 50 years while hospitalization data of se-
lected diseases show a steady increase in major NCD
cases [12]. Hospital data which is currently collected
only from the state sector show an increasing trend in
hospitalization for NCD such as diabetes, hypertensive
disease and ischemic heart diseases and mortality re-
ports indicate that leading causes of deaths in public
hospitals are cerebrovascular disease, acute myocardial
infarction and heart failure [10,11]. As the elderly popu-
lation of Sri Lanka are increasing and NCD are seen
more in elderly [13,14] this adds a considerable strain to
an already overburdened healthcare system.
The current population of Sri Lanka is recorded as
20.2 million [15]. Of this 18.3% lives in the Urban sector,
77.3% in the Rural sector and the balance 4.4% in the Es-
tate sector. Health care services to the people of Sri
Lanka are provided by both public and private sectors.
There are around 1638 health institutions in public sec-
tor and around 186 in private sector [10]. The public
sector provides health care for nearly 60 percent of the
population and encompasses the entire range of prevent-
ive, curative and rehabilitative health care aspects. The
public health care institutions are classified into four
levels according to the facilities available at the hospital
by the Ministry of Health in Sri Lanka where level 1 has
the minimum facilities.
Of the total government expenditure, about 5% is allo-
cated to the health sector [11] and the public health care
facilities provide services free of charge to all. The
private sector provides mainly curative care services
[10]. Primary health care is provided at all public sector
hospitals by out-patient departments (OPDs) and the
regular management of NCD is by the medical and other
specialised clinics where specialist medical officers are
available. While no published data is available from the
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and inpatient services.
The Medical Supplies Division (MSD) of the Ministry
of Health estimates the annual country need of medi-
cines for public sector and the State Pharmaceuticals
Corporation (SPC) procures them by a tender system.
The MSD distributes the procured medicines to the gov-
ernment hospitals. The SPC also procures medicines for
their community pharmacies (Rajya Osu Sala outlets)
and through them, to other private health care facilities
such as pharmacies attached to private hospitals and
those owned by individuals and other private companies.
The exception is only for narcotics where the supply to
both public and private sectors is through the MSD.
All state hospitals have outdoor pharmacies that provide
medicines free of charge to those that seek treatment from
the outpatient departments and clinics of these institu-
tions. If medicines are unavailable the patients would have
to purchase these from pharmacies in the private sector.
As there is no established health insurance scheme this re-
sults in out of pocket expenses to the patient.
Previous studies on availability and affordability of
medicines in Sri Lanka have been conducted in limited
geographical areas [8,16,17]. Thus a national survey was
needed to ascertain availability, price and affordability in
all provinces of the island to provide a better under-
standing of the situation. This survey was therefore con-
ducted to identify the island wide availability of selected
EM needed for treatment of NCD in public health care
facilities and availability, price and affordability of those
medicines in the private sector. To the best of our
knowledge this is the first such island wide survey in Sri
Lanka.
Methods
A national survey covering all nine administrative prov-
inces was conducted to examine the availability and af-
fordability of selected EM for NCD. Methodology was
based on World Health Organization and Health Action
International Manual (WHO/HAI) 2nd edition [4]. It ex-
plains in detail the methodology to conduct a reliable
survey to measure availability and affordability of medi-
cines in a geographical area or country and allows for
international comparison.
Survey setting was outdoor pharmacies of public health
care facilities and private pharmacies situated throughout
the country. Outdoor pharmacies of public health care
facilities, community pharmacies of SPC (Rajya Osu
Sala outlets), outdoor pharmacies of private hospitals
and private community pharmacies were taken as survey
sectors as each sector has a difference pricing structure
and availability.
The administrative provinces of the country were chosen
as survey areas. The province’s major urban centre (mainpublic hospital) was identified to anchor the sample. A
complete list of all public health care facilities in the prov-
ince that is within three hours’ travel from the major
urban centre was created. For each survey area five public
health care facilities representing all levels were selected
and this always included the main public hospital of the
province. Private pharmacies that are nearest to the se-
lected public health care facility were identified and one
Rajya Osu Sala Outlet and a separate private hospital was
selected randomly for each public health care facility. An
additional list of hospitals and pharmacies were main-
tained as a backup list. The sample size was in accordance
with that recommended by the WHO/HAI Manual.
The WHO/HAI manual recommends to survey up to
50 medicines taken from global, regional and supple-
mentary lists. Supplementary list for this study was the
National List of Essential Medicines for Sri Lanka [18].
The surveyed medicines list included 9 medicines from
the global core list, 10 medicines from the regional core
list, and the rest from the SL-EML (Additional file 1: List
of medicines surveyed).
Eleven NCD were identified to select the medicines list.
Prevalence of the diseases and those that are managed in
general medical clinics were considered to identify the
most commonly treated NCD. The diseases identified
were cardiovascular diseases (hypertension, ischaemic
heart disease and heart failure), diabetes, asthma and
chronic obstructive pulmonary diseases (COPD), peptic
ulcers, osteoporosis, diseases of the thyroid, epilepsy,
Parkinsonism, psychiatric disorders, joint related disorders
(osteoarthritis, rheumatoid arthritis) and glaucoma.
Of the medicines surveyed 30 were stock items for all
levels of health care facilities. Eight and 6 medicines se-
lected should have been available as stock items in all in-
stitutions above level 2 and level 3 respectively. Only
one of the selected medicines was restricted to level 4
institutions as a stock item. Although cancers are cate-
gorized under NCD, medicines used for cancers were
not surveyed as patients with cancers are managed in se-
lected hospitals in the country.
Data collection
Information on availability and affordability was ob-
tained with an interviewer administered data collection
form which was the survey tool. It was developed using
the medicine price data collection form of the WHO/
HAI manual. Two main aspects were considered for
data collection: availability and prices of the medicines
to be surveyed. Availability data was collected from all
selected pharmacies. Prices were collected from all
pharmacies except those in public health care facilities.
The prices were not obtained from public health care
facilities as medicines are provided free of charge to pa-
tients from these institutions. Prices of generic equivalent
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and price of the innovator product of particular medicine
were collected.
A pilot study was done by the principle investigator to
find out the feasibility and limitation of carrying out the
survey. All data collectors were pharmacy undergra-
duates and they were trained comprehensively before
commencing the survey by conducting a workshop. Two
data collectors collected data from one survey area to
increase accuracy. Data from a single survey area were
collected within a day by the data collectors and accu-
racy of data was ensured by comparing data of the two
collectors from the same area. Data was collected from
January to March 2013.
The data entering file was developed using SPSS soft-
ware by the researchers. Data were entered by two per-
sons and crossed checked to ensure accuracy. Hard and
soft copies of data were stored for future reference.
Data analysis
The IBM SPSS statistic software (Version 21) and
Microsoft Excel 2007 were used for statistical analysis
such as calculating mean and median.
Availability of 50 essential medicines prescribed for
NCD was analyzed by determining the mean percentage
availability in survey areas, survey sectors, at hospital
levels and for individual medicines. The availability of
originator brand was determined for the private sector.
To describe the availability, following ranges were used
as reference [19].
1. <30% Very low
2. 30 – 49% Low
3. 50 – 80% Fairly high
4. >80% High
Determination of prices
To determine price of each medicine, the unit price was
taken for most medicines eg. price of a tablet, capsule, etc.
Some medicines were considered as a unit package since
they need to be bought as such eg. insulin vial, salbutamol
syrup bottle, alendronic acid blister pack. The prices were
taken in Sri Lankan Rupees (SLR) at the time of data col-
lection and converted to US dollars (USD). The Currency
conversion factor was taken according to WHO/HAI
methodology and was the day of starting data collection.
Currency values were taken from the Central Bank of Sri
Lanka (1 SLR = 0.0079 USD).
Median price of each medicine in local currency (SLR)
and US Dollars (USD), median price of lowest priced
generic (LPG) in relation to international reference price
(IRP) [20] (ie Median Price Ratio (MPR)), comparison of
MPR of originator brand (OB) and lowest price generics
were determined for individual medicines.MPR ¼ Median price of lowest priced generic
International referenceprice
MPR of OB and LPG ¼ Median price of originator brand
Medianpriceof lowestpricedgeneric
Affordability
Affordability was calculated considering Defined Daily
Dose (DDD) and cost for a month’s supply of each medi-
cine was determined using the salary of the lowest paid
unskilled government worker [20,21]. Affordability was
not calculated for drugs that do not have DDD.
Ethical considerations
Ethical approval was granted by the Ethics Review
Committee of Faculty of Medical Sciences, University of
Sri Jayewardenepura (ERC approval no. 678/12) and




One hundred and nine survey samples were selected from
the nine survey areas (administrative provinces). Five out-
door pharmacies of public health care facilities, 5 private
pharmacies (closest to each public health care facility), 1
semi government community pharmacy (Rajya Osu Sala
outlet) and 1 outdoor pharmacy of a private hospital
(closest to each public health facility, where present)
from each survey area were included in the sample.
There were 45 outdoor pharmacies of public health
care facilities, 46 private pharmacies, 10 Rajya Osu Sala
outlets and 8 outdoor pharmacies of private hospitals
in the final sample.
Availability
The availability of the selected medicine was considered
regardless of innovator/generic/branded generic.
Percentage availability in survey sectors
Island wide mean availability of medicines was 70.19%
(±0.2). The mean availability was 58% (±0.32) in the
public sector and 74.37% (±0.13) in the private sector.
The median availability was 54% in the public sector and
76.1% in the private sector. The mean percentage avail-
ability of all selected medicines was calculated for each
survey sector. The mean availability in the outdoor phar-
macies of public health care facilities, Rajya Osu Sala
outlets, private pharmacies and outdoor pharmacies of
private hospitals were 58% (±0.32), 89% (±0.16), 71%
(±0.23) and 63% (±0.23) respectively.
Overall, a fairly high availability (50-80%) of the me-
dicines for NCD was seen in the survey sample. Rajya
Osu Sala outlets had the highest availability among
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health care facilities had the lowest.Percentage availability in survey areas
The mean availability was survey areas (administrative
provinces) ranged between 50 – 80% in 8 and was more
than 80% in one.
The availability of medicines in survey sectors among
survey areas was further analyzed. Only one survey area
showed less than 50% availability (45%) in outdoor phar-
macies of public health care facilities. There were two
survey areas showing less than 50% availability in out-
door pharmacies of private hospital. Rajya Osu Sala and
private pharmacies showed more than 50% availability in
all survey areas.Mean percentage availability of medicines at hospital levels
There were 4, 13, 14, and 14 of levels 1, 2, 3 and 4
public health care facilities respectively in the sample.
Although 45/50 surveyed medicines should have been
available in level 4 public hospitals, availability was
only 64.6%. The mean percentage availability according
to the levels of public health care facilities is given
in Figure 1.
Of the stock medicines (30/50) that should have been
available in Level 1 institutions,the availability was only
36.4%. The single medicine (alendronic acid) that was
supplied only to level 4 institutions, showed an availabi-
lity of 30.8%.Figure 1 Availability of essential medicines according to the levels ofMean percentage availability for individual medicines
The individual mean availability of 18 EM was >80%.
Twenty EM had an availability in the range of 50% to
80%. Mean availability of 11 medicines was between 30%
and 49%.
The availability of medicines was determined accord-
ing to therapeutic groups for particular disease such as
cardiovascular disorders, diabetes and asthma in survey
samples. Availability of selected medicines according
to the therapeutic groups is given in Figures 2,3 and
Table 1.
There was 0% availability of syrup sodium valproate
in public health care facilities. A very low availability
(0 - 30%) was seen with aspirin 100 mg, gliclazide 80 mg,
ipratropium bromide 40 μg, levodopa-carbidopa 100 +
25 mg, lithium carbonate 300 mg, ranitidine 150 mg,
and timolol 25% ophthalmic solution in the public
sector.
Mean availability of originator brands
The mean availability of originator brands was deter-
mined only for the private sector including Rajya Osu
Sala outlets. It was not considered for outdoor phar-
macies of public health care facilities as public sec-
tor gives priority to procure the lowest priced
generics. Only 30 originators were available in pri-
vate pharmacies. Total availability of originator
brand was 25.9%. Seven originators had a fairly high
availability (50 - 80%). Three originator brands had
an availability between 50-30% while 20 showed less
than 30% availability.public health care facilities.
Figure 2 Availability of medicines for diabetes.
Figure 3 Availability of medicines for bronchial asthma.
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Table 1 Availability of cardiovascular drugs in survey sectors










Atenolol 50 mg 44% 90% 70% 63% 66%
Glyceryltrinitrate 500 μg 93% 90% 30% 50% 66%
Amlodipine 5 mg 37% 100% 89% 50% 70%
Amiodarone 100 mg 50% 80% 33% 38% 46%
Digoxin 62.5 μg 29% 20% 33% 25% 27%
Verapamil 40 mg 96% 100% 89% 75% 87%
Enalapril 5 mg 98% 100% 100% 88% 96%
Captopril 25 mg 100% 100% 89% 75% 89%
Hydrochlorothiazide 25 mg 98% 50% 67% 75% 73%
Methyldopa 250 mg 58% 100% 72% 50% 70%
Nifedipine20 mg 98% 100% 91% 88% 94%
Carvedilol 6.25 mg 62% 100% 61% 63% 66%
Furosemide 40 mg 91% 100% 100% 88% 95%
Spironolactone 100 mg 38% 60% 72% 13% 52%
Atorvastatin 10 mg 91% 100% 87% 88% 91%
Simvastatin 20 mg 2% 100% 54% 38% 49%
Mean availability of cardiovascular drugs 68% 91% 74% 63% 74%
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Median price of each medicine in local currency and US
Dollars
There were 38 EMs less than 10 SLR and 5 medicines
more than 500 SLR. Out of 50 medicines, 41 medicines
prices were less than 1 USD and only two medicines
were priced more than 10 USD.
The median prices of originator brands (OB) were
calculated and they were compared with lowest priced
generic (LPG). The results are shown in Figure 4.Figure 4 Comparison of prices of the lowest price generic (LPG) andMedian price in relation to the international reference
price (Median Price Ratio (MPR))
MPR was calculated for 41 medicines with an IRP. The prices
of 21 medicines were less than IRP of the particular generic
medicine. The MPR was more than 5 for only one medicine.
Comparison of MPR of originator brand and lowest price
generics
MPR of originator and lowest priced generic was taken.
There were 14 medicines with ratio between 1–5. Thethe originator brand in US Dollars.
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times of LPG of particular medicines.
In most instances (96.6%) the originator brand price
was considerably higher than lowest priced generics.
Affordability
More than 67% of medicines required less than a single
day’s wages to purchase those medicines for a period of one
month. Less than ten days’ wages was required to buy a
month’s supply of 14 of the selected medicines (Table 2).
Discussion
Compared to studies done in other countries [7,8] mean
and median availability of surveyed essential medicines for
NCD in both public and private sectors is fairly high in Sri
Lanka. The public sector in Sri Lanka shows an improve-
ment in median availability from 28% in 2006 [8] to 54% in
2013.The Rajya Osu Sala outlets which represent the gov-
ernment private sector community pharmacy chain system,
had a high mean availability (89%) of medicines in 2013.
Every level of public hospital had a fairly high availability
of the EM surveyed. Although sodium valproate liquid
preparation should be available in all levels of public health
care facilities excluding level 1, it had a 0% availability. This
is similar to the findings of a previous study which showed
0% availability for carbamazepine syrup [17]. The unavail-
ability of these medicines could be due to the absence of an
EML for paediatric medicines. When compared with previ-
ous studies, availability of cardiovascular medicines in the
public sector showed a significant improvement [8,22].
The procurement and distribution system of MSD
affects availability of medicines in the public sector. The
low availability of some EM such as levothyroxine,
levodopa-carbidopa, and lithium carbonate in publicTable 2 The medicines that require more than one day’s wag
Medicines
Amiodarone 100 mg tablet for cardiovascular diseases
Beclometasone 200 μg capsules for bronchial asthma
Carvedilol 6.5 mg tablet for cardiovascular diseases
Glyceryl trinitrate 500 μg tablet for angina
Insulin (soluble) 100 IU/ml vial for diabetes
Intermediate acting insulin 10 IU/ml vial for diabetes
Ipratropium bromide 40 μg capsule for bronchial asthma
Levodopa- carbidopa 100 + 25 mg tablet for parkinsonism
Methyldopa 250 mg tablet for cardiovascular diseases
Phenytoin 100 mg tablet/capsule for epilepsy
Salbutamol 100 μg inhalation (MDI) for bronchial asthma
Simvastatin 20 mg tablet/capsule for cardiovascular diseases
Sodium valproate 200 mg tablet for epilepsy
Sodium valproate 200 mg/5 ml syrup for epilepsysector health care facilities is a concern that needs to be
addressed.
Availability of surveyed originator brands was very low
(25.9%) and these were available only in very few private
pharmacies. There were significant differences between
the originator and generic availability. Generics had a
high (>80%) or a fairly high (50 – 80%) availability in the
private sector. Although two thirds of the registered ori-
ginator brands were not available, there were many ge-
nerics available for a particular medicine.
Although aspirin 300 mg showed an overall availability of
78%, the 100 mg tablets had a low overall availability of
< 50%. This is a potential issue as low dose aspirin
(75-150 mg) is indicated for ischaemic heart disease.
Salbutamol MDI which is widely prescribed as a reliever for
acute asthma had an availability of only 55.6% in the public
sector while salbutamol 4 mg tablet and syrup (2 mg/5 ml)
were highly available 95.6% and 93.3% respectively.
Although salbutamol tablets are not included in the 17th
WHO Model List for Essential Medicines (EML) [23],
Sri Lanka continues to retain this in national guidelines
[24], EML and Hospital Formulary List (CAW: personal
communication) as the inhaled forms are expensive.
The high availability of atorvastatin when compared to
simvastatin is likely due to the former being included in the
SL-EML [18].
The lower median prices of some of the surveyed medi-
cines when compared to their IRPs suggest that these medi-
cines are cheaper than in the reference countries. This
indicates that generic pricing in private pharmacies and
Rajya Osu Sala outlets is appropriate. This finding is con-
sistent with the prices reported previously [16].
A monthly prescription for 31 individual medicines
was affordable to the lowest paid unskilled governmente to buy the monthly requirement
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daily wages to buy the monthly requirement of medi-
cines using LPG. Therefore medicines are generally
affordable to the lowest income community in the
country and this finding is consistent with that of
previous studies [8,16].
The relatively low availability of medicines in outdoor
pharmacies of public health care facilities is a concern as
the MSD should supply the medicines surveyed to all
institutions selected in the survey. The resultant out of
pocket expense to the patient could lead to non compli-
ance depending on the patient’s financial status.
Limitations
This survey was conducted at the beginning of the year
where most medicines are expected to be available in
public health care facilities. Availability may change
depending on the time of the year and hence these fin-
dings may not reflect the situation throughout the year.
Although affordability was calculated based on the daily
wage of an unskilled government worker there may be
people with an income less than this and thus the affor-
dability data may not be a true reflection of affordability.
Conclusions
Over all availability of EM for NCD was fairly high in
both public and private sectors at the time of surveying.
The availability of many generic brands and generics in
private pharmacies including the Rajya Osu Sala outlets
provide patients with an opportunity to purchase medi-
cines within their budget and the people need to be edu-
cated about this option.
The comparatively lower availability of EM in outdoor
pharmacies of public health care facilities needs to be
improved. Existing policies and procedures should be
strengthened to forecast requirements and for timely
procurement to ensure a steady and uninterrupted
supply to the public health care facilities. This will im-
prove both availability and affordability to a vast majority
of the country’s population which in turn will reduce the
morbidity and mortality of NCD.
Additional file
Additional file 1: List of medicines surveyed.
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